Autopsy report · NCT06207058

Evaluation of a Screen and Treat Protocol for Influenza

“Limited enrollment opportunities due to low rates of viral infections”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 6 months before it stopped.
• 25 participants enrolled.
• Results were posted on the registry 11 months after it ended.

Vital statistics

Status

Terminated

Sponsor

Tricore, Inc

Sponsor type

University, hospital or other

Conditions

Influenza

Interventions

Baloxavir Marboxil

Participants

25

Sites

1

Countries

United States

Trials that died the same way

• Therapy of the Skeletal Disease of Type 2 Diabetes With Denosumab
  “Due to enrollment difficulties compounded by the COVID pandemic.” (66% match in meaning)
• Tacks Versus Glue for Mesh Fixation in Laparoscopic Ventral Hernia Repair Treating Defects Between 2 and 5 cm Width
  “Limited patient enrollment” (66% match in meaning)
• Novel SARS-CoV-2 Point-of-care Testing
  “failure in enrolling eligible subjects during COVID-19 outbreaks” (65% match in meaning)
• The Effect of Thalidomide in Suppression of the Systemic Inflammatory Response Syndrome in Hemodialysis Patients
  “Low enrollment -- We could not recruit patients willing to be enrolled” (65% match in meaning)
• Effects of High Caffeine Content Coffee on Blood Pressure in Young Adults
  “not possible to enroll during COVID pandemic” (64% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.